• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估莱姆病的临床和经济结局:系统评价。

Clinical and economic outcomes evaluated in Lyme disease: a systematic review.

机构信息

University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

University of Maryland Institute of Human Virology, Baltimore, Maryland, USA.

出版信息

Parasit Vectors. 2020 Jul 9;13(1):341. doi: 10.1186/s13071-020-04214-y.

DOI:10.1186/s13071-020-04214-y
PMID:32646476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7346351/
Abstract

BACKGROUND

The financial implications of Lyme disease (LD) can vary widely for both the health system and the individual patients experiencing the disease. The aim of this review was to summarize published data on clinical and economic outcomes associated with LD.

METHODS

A literature review was conducted to identify all studies of LD that incorporate both clinical outcomes and costs. Included studies were described and categorized based on costs consistent with best practices used in economic evaluation.

RESULTS

The most frequent costs identified focused on formal health costs and productivity losses were the most common costs identified outside of the health system. Travel and informal care costs were less frequently reported. Clinical and economic outcomes of LD are primarily studied through economic models or observational analyses and focus on formal health care.

CONCLUSIONS

This review provides and overview of existing evidence and recommendations for future economic analyses in LD.

摘要

背景

莱姆病(LD)对卫生系统和患有该病的个体患者的财务影响可能差异很大。本综述的目的是总结与 LD 相关的临床和经济结果的已发表数据。

方法

进行文献综述,以确定所有纳入临床结果和成本的 LD 研究。根据经济评估中使用的最佳实践,对纳入的研究进行描述和分类。

结果

确定的最常见成本主要集中在正规医疗费用上,而在卫生系统之外,最常见的成本是生产力损失。旅行和非正式护理成本的报告较少。LD 的临床和经济结果主要通过经济模型或观察性分析进行研究,重点是正规医疗保健。

结论

本综述提供了 LD 现有证据的概述,并为未来的经济分析提出了建议。

相似文献

1
Clinical and economic outcomes evaluated in Lyme disease: a systematic review.评估莱姆病的临床和经济结局:系统评价。
Parasit Vectors. 2020 Jul 9;13(1):341. doi: 10.1186/s13071-020-04214-y.
2
The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review.莱姆病的经济负担和莱姆病干预措施的成本效益:范围综述。
PLoS One. 2019 Jan 4;14(1):e0210280. doi: 10.1371/journal.pone.0210280. eCollection 2019.
3
Economic impact of Lyme disease.莱姆病的经济影响。
Emerg Infect Dis. 2006 Apr;12(4):653-60. doi: 10.3201/eid1204.050602.
4
Estimating direct healthcare costs attributable to laboratory-confirmed Lyme disease in Ontario, Canada: A population-based matched cohort study using health administrative data.估算加拿大安大略省实验室确诊莱姆病的直接医疗费用:一项基于人群的匹配队列研究,使用卫生行政数据。
Zoonoses Public Health. 2019 Jun;66(4):428-435. doi: 10.1111/zph.12560. Epub 2019 Jan 21.
5
Health care costs, utilization and patterns of care following Lyme disease.莱姆病后的医疗保健成本、利用率及护理模式。
PLoS One. 2015 Feb 4;10(2):e0116767. doi: 10.1371/journal.pone.0116767. eCollection 2015.
6
Lyme disease--what is the cost for Scotland?莱姆病——对苏格兰来说代价是什么?
Public Health. 2003 Jul;117(4):264-73. doi: 10.1016/S0033-3506(03)00067-2.
7
Lyme borreliosis in Belgium: a cost-of-illness analysis.比利时莱姆病:疾病负担分析。
BMC Public Health. 2022 Nov 28;22(1):2194. doi: 10.1186/s12889-022-14380-6.
8
[A systematic review on population-based indicators of the quality of care in formal and informal provider networks and their application in health economic evaluations].[关于正规和非正规医疗服务提供网络中基于人群的医疗质量指标及其在卫生经济评估中的应用的系统评价]
Z Evid Fortbild Qual Gesundhwes. 2019 Aug;144-145:7-23. doi: 10.1016/j.zefq.2019.06.004. Epub 2019 Jul 19.
9
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
10
Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders预防和治疗精神、神经及物质使用障碍的干预措施、政策和平台的成本效益及可负担性

引用本文的文献

1
Forty Years of Evidence on the Efficacy and Safety of Oral and Injectable Antibiotics for Treating Lyme Disease of Adults and Children: A Network Meta-Analysis.四十年口服和注射用抗生素治疗成人和儿童莱姆病疗效和安全性的证据:网状荟萃分析。
Microbiol Spectr. 2021 Dec 22;9(3):e0076121. doi: 10.1128/Spectrum.00761-21. Epub 2021 Nov 10.
2
Diseases Transmitted by the Black-Legged Ticks in the United States: A Comprehensive Review of the Literature.美国黑腿蜱传播的疾病:文献综述
Cureus. 2021 Aug 28;13(8):e17526. doi: 10.7759/cureus.17526. eCollection 2021 Aug.
3
Comparative Cost and Effectiveness of a New Algorithm for Early Lyme Disease Diagnosis: Evaluation in US, Germany, and Italy.

本文引用的文献

1
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.阿尔茨海默病干预措施成本效用分析中的家庭和照护者溢出效应。
Pharmacoeconomics. 2019 Apr;37(4):597-608. doi: 10.1007/s40273-019-00788-3.
2
The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review.莱姆病的经济负担和莱姆病干预措施的成本效益:范围综述。
PLoS One. 2019 Jan 4;14(1):e0210280. doi: 10.1371/journal.pone.0210280. eCollection 2019.
3
The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra.
早期莱姆病诊断新算法的成本效益比较:在美国、德国和意大利的评估
Clinicoecon Outcomes Res. 2021 May 26;13:437-451. doi: 10.2147/CEOR.S306391. eCollection 2021.
经济评估中纳入溢出效应:并非可有可无。
Pharmacoeconomics. 2019 Apr;37(4):451-456. doi: 10.1007/s40273-018-0730-6.
4
The allocation of time and risk of Lyme: A case of ecosystem service income and substitution effects.莱姆病的时间分配与风险:一个生态系统服务收入和替代效应的案例。
Environ Resour Econ (Dordr). 2018 Jul;70(3):631-650. doi: 10.1007/s10640-017-0142-7. Epub 2017 Apr 13.
5
Motivations and Experiences of Canadians Seeking Treatment for Lyme Disease Outside of the Conventional Canadian Health-Care System.加拿大人在加拿大传统医疗体系之外寻求莱姆病治疗的动机与经历。
J Patient Exp. 2018 Jun;5(2):120-126. doi: 10.1177/2374373517736385. Epub 2017 Oct 31.
6
Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease.持久性莱姆病症状患者中,较长时间与较短时间使用抗生素的成本效益比较。
PLoS One. 2018 Apr 2;13(4):e0195260. doi: 10.1371/journal.pone.0195260. eCollection 2018.
7
Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].医疗保健价值的定义要素——一种卫生经济学方法:一份ISPOR特别工作组报告[3]
Value Health. 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007.
8
Practices of Lyme disease diagnosis and treatment by general practitioners in Quebec, 2008-2015.2008 - 2015年魁北克全科医生对莱姆病的诊断与治疗实践
BMC Fam Pract. 2017 May 22;18(1):65. doi: 10.1186/s12875-017-0636-y.
9
The cost of Lyme borreliosis.莱姆病的成本。
Eur J Public Health. 2017 Jun 1;27(3):538-547. doi: 10.1093/eurpub/ckw269.
10
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.《健康与医疗领域成本效益分析的实施、方法学实践和报告推荐:第二版》。
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.